New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

 

OSAKA, Japan & CAMBRIDGE, Mass. - 

Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms

Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies

Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway

 

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1.

"People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-861-3001) Phase 3 study. “The newly published Phase 3 data reinforce the potential of oveporexton to transform how we approach narcolepsy type 1 in clinical practice, shifting from managing individual symptoms to treating the disease itself.”

NT1 is a chronic, rare neurological disease driven by orexin deficiency. As a result, people experience a range of daytime and nighttime symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disrupted nighttime sleep, sleep paralysis, hallucinations and cognitive symptoms. The persistent, 24 hour-nature of the disease can severely impact many aspects of a person’s life, including work, education and social interactions.

“Leveraging the extensive research we conducted on the impact of narcolepsy type 1, we designed our comprehensive Phase 3 program to reflect the complexity of the disease and the experiences of those living with it,” said Sarah Sheikh, M.Sc., B.M., B.Ch., MRCP, Head, Neuroscience Therapeutic Area Unit and Global Development at Takeda. “The magnitude of effect seen across the full range of symptoms evaluated reinforces the potential of oveporexton to redefine how people feel on treatment. We are grateful to the patients, caregivers and healthcare providers who have participated in our studies and are thrilled to bring the first orexin agonist to the community.”

FirstLight and Radiant Light Phase 3 Study Designs

The FirstLight (TAK-861-3001) study enrolled 168 participants randomized to one of three dosing arms (twice-daily 2mg, twice-daily 1mg and placebo). The RadiantLight (TAK-861-3002) study enrolled 105 participants randomized to two dosing arms (twice-daily 2mg and placebo). The 14 primary and secondary endpoints from the studies assessed the effect of oveporexton on the broad disease impact compared to placebo over 12 weeks. More than 95 percent of the participants who completed the studies enrolled in the ongoing long-term extension (LTE) study.

The data published in the New England Journal of Medicine included primary and key secondary efficacy results along with the safety and tolerability of oveporexton. Results from additional secondary and exploratory endpoints assessing quality of life measures and disease severity were also published.

Efficacy Results:

The two Phase 3 studies demonstrated consistent, clinically meaningful and statistically significant improvements compared to placebo in wakefulness, sleepiness, cataplexy, disease severity and quality of life measures (p-values of <0.001) across doses over 12 weeks. These improvements were observed at the earliest assessed timepoint for each measure and were sustained throughout the duration of the studies.

The median percent reductions in weekly cataplexy rate ranged from 79.0% to 88.8% with oveporexton versus 27.7% to 39.1% with placebo at week 12.

Oveporexton improved disease severity across all domains of the narcolepsy severity scale (NSS-CT) including EDS, cataplexy, hypnagogic hallucinations and sleep paralysis across both doses, and in the disrupted nighttime sleep domain with oveporexton 2mg. More than 70% of treated participants reported the lowest severity level on the NSS-CT (mild; score 0-14) across doses.

Nearly all treated participants (97%) reported improvements in overall narcolepsy symptoms as assessed by the self-rated Patient Global Impression of Change (PGI-C) scale.

All dose groups achieved normative thresholds for wakefulness on the Maintenance of Wakefulness Test (MWT) (≥20 minutes) and Epworth Sleepiness Scale (ESS) (score of ≤10). Most participants reached or exceeded normal thresholds for quality of life outcomes as measured by the 36-Item Short Form Survey (SF-36; secondary endpoint) and EuroQol-5 Dimensions 5-Levels (EQ-5D-5L; exploratory endpoint).2.3

Safety Results:

Consistent across clinical studies to date, the most commonly reported treatment-emergent adverse events (TEAEs) across both studies were transient insomnia, urinary urgency, urinary frequency and excessive saliva.

Most TEAEs were mild to moderate in intensity, started within two days of treatment and did not require medical intervention.

Most insomnia events resolved within one week and did not impair or impact daytime functioning, unlike traditional insomnia symptoms. Approximately half of urinary events resolved by week 12 and unresolved events were all mild or moderate in severity.

Oveporexton is the first and only orexin agonist approved in the United States, Japan and China to treat the disease holistically rather than individual symptoms. With additional regulatory submissions underway, Takeda continues to work with health authorities to bring oveporexton to more people living with NT1.

About Oveporexton (ORZEYFUL)

Oveporexton is an oral orexin receptor 2 (OX2R) agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency associated with narcolepsy type 1 (NT1). By activating OX2Rs, oveporexton promotes wakefulness and reduces abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy (sudden and temporary loss of muscle tone), to address a range of daytime and nighttime symptoms as evaluated in clinical studies and consistent with the approved label.

INDICATION

ORZEYFUL is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ORZEYFUL is contraindicated in patients taking strong CYP3A inhibitors.

WARNINGS AND PRECAUTIONS

Insomnia: In pooled phase 3 studies in patients with NT1, 60%, 55%, and 1% of patients in the ORZEYFUL 2 mg twice daily, ORZEYFUL 1 mg twice daily, and placebo groups, respectively, developed insomnia. Prior to ORZEYFUL treatment initiation, inform patients about the risk of insomnia at initiation of treatment. If insomnia persists beyond 7 days and significantly impacts daytime functioning or quality of life, consider ORZEYFUL dosage reduction or discontinuation.

Urinary Frequency and Urgency: ORZEYFUL may cause or worsen urinary frequency and urgency. In pooled phase 3 studies in patients with NT1:

58%, 53%, and 5% of patients in the ORZEYFUL 2 mg twice daily, ORZEYFUL 1 mg twice daily, and placebo groups, respectively, developed urinary frequency.

16%, 15%, and 1% of patients in the ORZEYFUL 2 mg twice daily, ORZEYFUL 1 mg twice daily, and placebo groups, respectively, developed urinary urgency.

These lower urinary tract symptoms are consistent with ORZEYFUL’s mechanism of action through agonism of the orexin receptor 2 (OX2R) on central micturition pathways. Prior to initiation of ORZEYFUL treatment, inform patients about the risk of urinary frequency and urgency and screen for lower urinary tract symptoms. Monitor ORZEYFUL-treated patients with a history of overactive bladder for worsening urinary tract symptoms.

Creatine Phosphokinase Elevations: In pooled phase 3 studies in patients with NT1, asymptomatic creatine phosphokinase elevations >5x ULN were observed in 11% (21/196) of ORZEYFUL-treated patients and 5% (4/76) of placebo treated patients. Two of these cases were characterized by markedly elevated CPK and transaminase levels; both patients discontinued treatment. None of the cases were associated with myoglobinuria or renal impairment. Advise patients to report unexplained muscle pain, weakness, or dark urine, particularly when engaging in vigorous physical activity or taking concomitant drugs associated with myotoxicity.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) reported in phase 3 studies with ORZEYFUL were insomnia, pollakiuria, micturition urgency, and salivary hypersecretion.

DRUG INTERACTIONS

Concomitant use with strong or moderate CYP3A inhibitors increases oveporexton exposures, which may increase the risk of ORZEYFUL-associated adverse reactions.

Concomitant use of strong and moderate CYP3A inducers can increase oveporexton metabolism and decrease plasma levels of oveporexton, which may decrease the effectiveness of ORZEYFUL.

USE IN SPECIFIC POPULATIONS

Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to ORZEYFUL during pregnancy. Patients should be encouraged to enroll in the ORZEYFUL pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-877-371-0309. Available data from clinical trials with ORZEYFUL use during pregnancy are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Lactation: There are no data available on the presence of oveporexton in human milk, the effects on the breastfed infant, or the effects on milk production. Animal studies indicate that oveporexton was present in the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk.

Hepatic Impairment: Avoid use of ORZEYFUL in patients with severe hepatic impairment (Child-Pugh C), as it has not been studied in this population.

Renal Impairment: Avoid use of ORZEYFUL in patients with severe renal impairment on dialysis (eGFR <15 mL/minute), as it has not been studied in this population.

DRUG ABUSE AND DEPENDENCE

ORZEYFUL contains oveporexton. Controlled substance schedule to be determined after review by the Drug Enforcement Administration.

ORZEYFUL has potential for abuse and misuse. Carefully evaluate patients for a recent history of drug abuse, especially those with a history of CNS stimulant, and follow such patients closely, observing them for signs of misuse or abuse of ORZEYFUL.

Important Note: Prescribing Information is subject to change pending DEA scheduling and final label publication.

Please click for Full Prescribing Information.

About Takeda’s Orexin Franchise

Takeda is the leader in orexin science with a tailored portfolio of investigational orexin agonists in pre-clinical and clinical stages for multiple-sleep wake disorders and other indications where orexin biology plays a role including respiration, mood and metabolism. Oveporexton is the lead orexin receptor 2 (OX2R) agonist in Takeda’s orexin franchise and has been approved by regulatory bodies in China for the treatment of narcolepsy type 1 (NT1) in adolescents aged 16 and older and adults as well as in the United States and Japan for adults with NT1. The company is also investigating other oral orexin agonists, including TAK-360 for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), as well as TAK-495.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References

1. Dauvilliers Y, Mignot E, Antczak J, et al. Oveporexton for Narcolepsy Type 1: Results from Two Phase 3 Trials. New England Journal of Medicine 2026.

2. Jiang R, Bas Janssen MF, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res 2021;30:803-16.

3. Maruish, M. E. User's Manual for the SF-36V2 Health Survey 2011. Lincoln, RI. 3rd ed.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909425335/en/

Permalink

https://aetoswire.com/en/news/0909202657200

Contacts

Investor Relations

Christopher O’Reilly

takeda.ir.contact@takeda.com

Media Relations

Tsuyoshi Tada (Tokyo)

Toiawase_kouhou@takeda.co.jp

Rachel Wallace (Boston)

Media_relations@takeda.com

 

LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation

 MUMBAI, India - 

Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes

(BUSINESS WIRE) -- LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation.

As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications.

Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address security challenges across increasingly complex open-source ecosystems.

Building on its long-standing status as an IBM Platinum Partner, LTM will help enterprises transform AI-driven vulnerability discovery into measurable remediation outcomes by leveraging Lightwell for open-source software dependencies. LTM plans to offer a comprehensive portfolio of services spanning remediation strategy, dependency analysis, risk-based prioritization, remediation program management, DevSecOps integration, testing and validation, and large-scale deployment support.

"As AI accelerates software development and vulnerability discovery, enterprises need a faster and more scalable approach to remediation. Lightwell represents a significant advancement in securing the open-source software supply chain by bringing AI-driven remediation and trusted software maintenance into the enterprise. Through our collaboration with IBM, LTM will help organisations strengthen their cyber resilience at scale," said Chandan Pani, Chief Information Security Officer, LTM.

Organizations across industries increasingly rely on open-source software as a foundation for digital innovation, making effective vulnerability remediation a critical component of cybersecurity and operational resilience. LTM’s expertise in application modernization, cloud, cybersecurity, and DevSecOps positions it to help enterprises integrate remediation strategies into their software engineering and security operations.

"Addressing today's software supply chain challenges requires a collective defense," said Sandip Patel, Managing Director, IBM India and South Asia. “As AI accelerates vulnerability discovery, collaboration across the ecosystem becomes increasingly important. Bringing LTM's engineering and transformation expertise to Lightwell can help enterprises mitigate risk and build more resilient software supply chains."

“AI-driven discovery has pressed the demand for speed and patch delivery far beyond the means of any one single vendor. A challenge of this magnitude requires an expert ecosystem, highlighted by partners like LTM, with the specialized skills and experience to not simply acknowledge a vulnerability, but to help customers of Lightwell via LTM's complementary services to accelerate delivery of Lightwell remediations into the customer's environment quickly to help prevent a zero-day exploit or production downtime,” said Ryan King, Vice President, AI and Infrastructure Partners, Red Hat.

LTM and IBM are committed to helping clients accelerate open-source innovation while reducing the operational burden of managing vulnerabilities across complex open-source environments, enabling organizations to innovate with confidence in an increasingly AI-driven world.

About LTM

LTM — a Larsen & Toubro Group company — is an AI-centric global technology services company and the Business Creativity partner to the world's largest enterprises. We bring human insights and intelligent systems together to help clients create greater value at the intersection of technology and domain expertise. Our capabilities span integrated operations, transformation, and Business AI—enabling new ways of working, new productivity paradigms, and new roads to value. Together with over 87,000 employees across 40 countries and our global network of partners, LTM owns outcomes for clients, helping them not just outperform the market, but Outcreate it. Read more at LTM.com.

About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901240226/en/

Permalink

https://www.aetoswire.com/en/news/0909202657201

Contacts

Media Contact

Gitanjali Sreepal, gitanjali.sreepal@ltm.com, Global Media Relations, LTM

 

Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities

 PARMA, Italy -

HIGHLIGHTS

H1 2026 revenues of €1.89 billion, up +3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area

Continued investment in innovation with €426 million invested in R&D (22.5% of sales)

Completed strategic investment for treatment of hereditary angioedema (HAE) with acquisition of KalVista Pharmaceuticals

EBITDA continues to remain close to 30%, reflecting continued strong profitability and disciplined resource allocation

Recent Economic Footprint study highlights Chiesi's contribution to economic development, supporting 56,488 jobs globally, generating €6.0 billion in GDP impact and €2.0 billion in taxes and public revenues worldwide

 

(BUSINESS WIRE) -- Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 ("H1 2026").

Performance across therapeutic areas and regions

Chiesi reported revenues of €1.89 billion, representing growth of +3.6% at constant exchange rates (CER) compared with H1 2025. These results do not include the impact of the recent acquisition of KalVista Pharmaceuticals.

The Group's growth is supported by continued expansion of its global rare diseases area (+€45m; +9.9% @CER), and sustained performance in neonatology and specialty care therapeutic areas (+6.5% @CER). The respiratory health area remains broadly stable (-0.8% @CER) fueled by the strong growth in our inhaled triple therapy portfolio.

Driven by the ongoing execution of its international growth strategy, Chiesi continued to expand its presence in key markets, with particularly strong momentum in the United States (+9.6% @CER), while maintaining resilient performance across Europe (+0.9% @CER) and a continuous development of the remaining geographies (+5.5% @CER).

EBITDA margin was 29.4%, reflecting continued strong profitability, disciplined resource allocation and operational focus. The Group also maintained solid cash generation from operations, enabling continued investment in its research pipeline, manufacturing capabilities, and strategic acquisitions.

Continued commitment to innovation

The focus on innovation remains central to Chiesi's strategy. During the first half of 2026, the Group invested €426 million in Research & Development, representing approximately 22.5% of revenues.

Investments were focused on advancing the pipeline across respiratory health, rare diseases and specialty care, while also supporting the development of the Group's Carbon Minimal Inhaler (CMI) platform and strengthening the industrial capabilities required to support its future rollout. This included the strategic partnership with Bespak, aimed at delivering lower carbon inhaled therapies through CMIs at scale, without compromising clinical choice or continuity of care for patients.

During the first half of the year, Chiesi also completed the acquisition of KalVista Pharmaceuticals, a US-based pharmaceutical company with a differentiated oral, on demand treatment for hereditary angioedema (HAE), further strengthening its global rare disease platform and pipeline in areas of high unmet medical need.

Creating positive impact beyond healthcare: Chiesi's Economic Footprint

Chiesi's impact extends well beyond the healthcare solutions it delivers to patients. According to its recent Economic Footprint assessment conducted with PwC Italy (part of an international professional services network), in 2025 the Group generated approximately €6 billion in total GDP worldwide, supported 56,488 jobs, and contributed nearly €2 billion in taxes and public revenues across the countries in which it operates.

As a European-headquartered company with innovation deeply rooted across the region, Chiesi generated €4.1 billion in total GDP across Europe, supported almost 30,000 jobs and contributed approximately €1.4 billion in taxes and public revenues. The study also found that Europe accounted for 78% of Chiesi's global R&D investment and 60% of all suppliers engaged by the Group, highlighting the region's central role in driving innovation, employment and economic growth.

At the same time, Chiesi continues to expand its contribution in key international markets, generating more than €1.1 billion in GDP impact in the U.S. while supporting almost 4,000 jobs in the country. It also contributes €800 million in GDP impact across China, Brazil, Australia, Mexico and rest of the world, and more than 22,000 jobs across these markets.

These findings demonstrate Chiesi's long-standing commitment to strengthening the overall healthcare ecosystem and creating value for patients, healthcare systems, local communities and economies across the world.

Jean Marc Bellemin, CFO and Interim CEO of Chiesi Group, commented:

"Our first-half results for 2026 reflect the resilience of our strategy and the strength of our global footprint. As we continue to deliver a solid performance, we remain focused on innovation, sustainable growth, and creating long-term value for patients, society and the environment. The acquisition of KalVista further strengthens our position in rare diseases and expands our presence in the U.S., while our Economic Footprint study illustrates Chiesi’s broader contribution to the economies and communities in which we operate. We remain focused on combining sustainable growth with continued innovation and long-term value creation for patients and society.”

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.

By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909964444/en/

Permalink

https://www.aetoswire.com/en/news/0909202657194

Contacts

Press Info:

Anna Bonisoli Alquati, Head of Global External Communications: mediarelations@chiesi.com

Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com

Davide Paterlini, Global External Communications Sr. Manager: mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com

EIG Announces Final Close of Senior Infrastructure Debt Fund VI With $4.0 Billion Raised Across Its Direct Lending Platform

 WASHINGTON - Wednesday, 09. September 2026 AETOSWire Print 

Platform exceeds original $3 billion fundraising target, reflecting broad institutional demand for infrastructure credit

(BUSINESS WIRE) -- EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the final close of EIG Senior Infrastructure Debt Fund VI (“SIDF VI”) at $1.9 billion, nearly double the size of its predecessor fund. Together with $2.1 billion committed to single investor vehicles, this exceeds the strategy's original $3 billion target and reflects strong demand from investors seeking customized and evergreen exposure to senior infrastructure debt.

Since launching in July 2024, SIDF VI has already committed approximately $1 billion across 16 investments, reflecting strong proprietary origination capabilities.

SIDF VI seeks to make directly originated, senior secured debt investments across a broad range of sectors, including power generation, renewable energy, energy transition infrastructure, midstream and other critical infrastructure, with a primary focus on opportunities in the United States and Europe. The strategy draws on EIG's longstanding relationships with sponsors, developers, infrastructure operators, and corporate counterparties to source and structure investment opportunities globally.

“We believe we are entering one of the most significant energy-related infrastructure investment cycles in decades. The strong support for SIDF VI demonstrates that investors increasingly recognize the critical role that private capital will play in financing the energy, power, and infrastructure systems underpinning modern economies. We are grateful for the trust our investors have placed in EIG and remain committed to being disciplined stewards of their capital,” said R. Blair Thomas, Chief Executive Officer of EIG.

"We are pleased to close SIDF VI with strong support from a global investor base and encouraged by what the platform has already accomplished,” said Andrew Ellenbogen, President of EIG and CEO of EIG Credit Management. “The combination of significant commitments to both the fund and our single investor vehicles, including evergreen structures, highlights investors’ desire for flexible ways to access the strategy. The pace of deployment since launch reflects both the breadth of investment opportunities we are seeing across energy and infrastructure and the strength of EIG's origination platform, relationships and underwriting discipline."

“Energy demand growth, electrification and grid modernization are converging to create a significant need for capital. In our view, this is creating a generational opportunity in infrastructure credit. As financing needs continue to grow and traditional capital providers become more constrained, private credit can play an increasingly important role in funding critical energy and infrastructure assets worldwide,” said Rob Johnson, President and Chief Investment Officer of EIG Credit Management.

The Direct Lending platform received strong support from both existing and new investors across North America, Europe, Asia-Pacific, and the Middle East, reflecting broad institutional demand for energy and infrastructure credit strategies. Investors include public and corporate pension plans, sovereign wealth funds, insurance companies, financial institutions, asset managers, endowments, foundations, and other institutional investors.

Kirkland & Ellis LLP provided legal counsel to EIG, Campbell Lutyens served as placement agent, and Scotiabank acted as structuring agent for the rated note feeder in connection with the formation and fundraising of SIDF VI.

For additional information about the fund, please reach out to investorrelations@eigpartners.com.

About EIG

EIG is a leading institutional investor in the global energy and infrastructure sectors with $27.1 billion assets under management as of June 30, 2026. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 44-year history, EIG has committed over $55 billion to the energy sector through 429 projects or companies in 44 countries on six continents. EIG’s clients include many of the leading pension plans, insurance companies, endowments, foundations and sovereign wealth funds in the U.S., Asia and Europe. EIG is headquartered in Washington, D.C. with offices in Houston, London, Sydney, Rio de Janeiro, Hong Kong and Seoul. For additional information, please visit EIG’s website at www.eigpartners.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909322713/en/

Permalink

https://www.aetoswire.com/en/news/0909202657198

Contacts

Media Contacts

EIG

FGS Global

Kelly Kimberly / Brandon Messina

+1 212-687-8080

EIG@fgsglobal.com

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

TOKYO - Wednesday, 09. September 2026

- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach –

Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A.

Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A.

First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously.

 

(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been awarded the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific honors.

Hemophilia A is caused by a deficiency of coagulation Factor VIII, one of the proteins required for normal blood clotting. When activated, Factor VIII serves as a bridge that facilitates the activation of Factor X by activated Factor IX on the surface of activated platelets. The award recognizes the unconventional concept of replacing this function of Factor VIII with a bispecific antibody, which enabled prolonged therapeutic activity, the convenience of subcutaneous administration, and sustained bleed prevention regardless of the presence or absence of Factor VIII inhibitors (antibodies), thereby making a significant contribution to addressing unmet medical needs in hemophilia A.

The Lasker Awards are among the most respected medical research awards in the United States, honoring individuals who have made significant contributions to medical science and public health. They are presented in the fields of basic medical research, clinical medical research, and public service. This marks the second time Japanese researchers have received the award in the clinical medical research category since the inception of the Lasker Awards in 1945, and the first time that three Japanese researchers have been recognized simultaneously in this category.

Emicizumab is an antibody drug created through extensive research conducted by Chugai scientists. Conventional antibody therapeutics typically exert their effects through a “subtractive” approach, inhibiting the activity of disease-related molecules or cells, or eliminating target cells through immune-mediated mechanisms. In contrast, emicizumab became the world's first antibody medicine to embody an “additive” approach, restoring a missing biological function by endowing the antibody itself with a function normally performed by a different protein*. It is also the world's first recombinant full-length IgG bispecific antibody therapeutic designed to bind two different targets. During its creation, Chugai also developed and applied its proprietary antibody engineering technology, ART-Ig, which enabled commercial-scale manufacturing.

The realization of this treatment was made possible through collaboration with Nara Medical University, which possesses extensive expertise in both basic and clinical research on hemophilia. Emicizumab was licensed out to Roche and Chugai worked together with Roche and Genentech to advance global clinical development and regulatory submissions, ultimately bringing the product to patients as Hemlibra. Following its approval in the United States in 2017 and in Japan and Europe in 2018, Hemlibra is now approved in more than 120 countries and regions worldwide**. An integrated analysis of the phase III HAVEN 1–4 studies demonstrated that, regardless of the presence or absence of factor VIII inhibitors, disease severity, or age, the primary endpoint of the annualized bleeding rate (ABR) for treated bleeds over 24-week intervals throughout the study was 1.4 events per year. Moreover, 70.8% of participants (277/391) experienced zero treated bleeds during Weeks 1–24, and this proportion increased over time to 82.4% (140/170) during Weeks 121–144. No new safety signals were identified, and the most common adverse event was injection-site reactions (27.8%).¹ In addition to providing sustained bleed prevention regardless of the presence or absence of factor VIII inhibitors, emicizumab offers a new treatment option by not inducing new factor VIII inhibitors and improving convenience through subcutaneous administration and extended dosing intervals. To date, it has been used by more than 30,000 people with hemophilia A worldwide (cumulative global total as of June 30, 2026).

*As of 2023, among approved antibody drugs, emicizumab was the first drug in which the antibody itself substitutes for the function of a different protein that is deficient or dysfunctional.

** This product was evaluated and approved based on a clinical data package that included results from clinical studies involving dosing regimens not approved in Japan. Therefore, this document may contain descriptions that differ from the approved dosage and administration in Japan.

Dr. Osamu Okuda, Chugai's President and CEO, commented, “I am truly delighted that this original concept, inspired by our desire to reduce the burden on people with hemophilia A and their families, together with the innovative drug discovery technologies that brought it to life, has been recognized through this prestigious award. Emicizumab has delivered sustained bleed prevention regardless of the presence or absence of inhibitors, disease severity, or age, while reducing treatment burden through subcutaneous administration once every one to four weeks*, thereby bringing a new everyday life to people with hemophilia A and their families. I would like to extend my heartfelt congratulations to the three researchers and express my profound respect for their creativity, leadership, and perseverance in tackling formidable challenges, as well as for the many individuals whose dedication and contributions to research and development made this achievement possible.

“This scientific breakthrough could not have been realized as Hemlibra and delivered to people with hemophilia A around the world without the collaboration and support of healthcare professionals, including those at Nara Medical University, as well as our partners at Roche and Genentech. I would also like to express my sincere gratitude to all those who have supported this endeavor over many years.

“Looking ahead, we will continue to strengthen our proprietary technologies and scientific capabilities while promoting collaboration with diverse partners. Through these efforts, we remain committed to delivering innovative drugs and services to patients around the world.”

Summary of Award

Award

Lasker-DeBakey Clinical Medical Research Award

For invention of a bispecific antibody that joins blood clotting Factors IX and X, restoring the deficient Factor VIII activity in hemophilia A and preventing the severe bleeding in this hereditary disorder

Laureates

Dr. Kunihiro Hattori, former Senior Fellow of Chugai

Dr. Takehisa Kitazawa, Deputy Head of Research Division, Chugai

Dr. Tomoyuki Igawa, Head of Research Division, Chugai

Achievement Recognized

Hemophilia A is a bleeding disorder caused by a deficiency of coagulation Factor VIII. Rather than replacing Factor VIII itself, Hattori and team pursued a novel concept of substituting its function with an antibody. They developed a bispecific antibody that bridges activated Factor IX and Factor X at the appropriate orientation and spatial position on the surface of activated platelets, leading to the creation of ACE910 (later named emicizumab). They also developed ART-Ig, a proprietary antibody-engineering technology that improves expression and purification efficiency for commercial-scale manufacturing. The significance of this work lies in its demonstration of a groundbreaking concept that redefined the capabilities of antibody therapeutics and transformed the treatment paradigm for hemophilia A.

 

Emicizumab provides sustained bleed prevention regardless of the presence or absence of Factor VIII inhibitors (antibodies). Through the convenience of subcutaneous administration and extended dosing intervals, it has helped reduce the treatment burden for people with hemophilia A and their families. 

Award Ceremony

Thursday, September 17, 2026 (EDT)

Venue: The Pierre Hotel (New York, NY, USA)

Program: Luncheon and acceptance remarks by laureates

Remarks from Laureates

Dr. Kunihiro Hattori:

Contribution: Originated the concept of a bispecific antibody based on expertise in blood coagulation and antibodies, and led the research project

“I am deeply honored that our collective efforts, together with many researchers and clinicians, dedicated to advancing science for society and for patients, have been recognized through this award. I believe our continuing mission is to ensure that this treatment reaches patients around the world who can benefit from it.”

Dr. Takehisa Kitazawa:

Contribution: Led pharmacology and biology research, advancing the discovery of the candidate antibody and the demonstration of factor VIII-mimetic activity

“It has been a privilege to contribute to the creation of emicizumab through collaboration with numerous healthcare professionals and fellow researchers. I would also like to extend my heartfelt gratitude to the people with hemophilia A and their families who participated in the clinical studies. I hope this recognition will inspire further innovation, and I remain committed to advancing the next generation of scientific breakthroughs.”

Dr. Tomoyuki Igawa:

Contribution: Led the design of emicizumab and the establishment of technologies for the efficient manufacturing of bispecific antibodies

“The desire to lessen the burden on patients and their families while helping them lead fuller lives has motivated us to overcome many scientific challenges. I am truly honored that the three of us have received such a prestigious award together. We will continue to pursue innovative drugs that make a meaningful difference in people’s lives through scientific excellence and creative thinking.”

For biographies of the laureates, please click here.

About Hemophilia A2,3

Hemophilia is primarily classified into two types, hemophilia A and hemophilia B. Hemophilia A is a bleeding disorder caused by a deficiency of a protein called coagulation factor VIII (FVIII), which is essential for normal blood clotting. As a result, people with hemophilia A have difficulty forming blood clots. Hemophilia A can be either congenital, caused by an inherited genetic abnormality, or acquired, which develops later in life. Congenital hemophilia A predominantly affects males and occurs in approximately one in 5,000 male births. Occurrence in females is extremely rare because congenital hemophilia A is an X-linked recessive disorder.

Symptoms associated with bleeding in hemophilia A vary, but a characteristic feature of the disease is the frequent occurrence of internal bleeding that is not externally visible. Internal bleeding can lead to the formation of hematomas, or localized collections of blood, which may compress surrounding nerves and blood vessels, causing pain and functional impairment. Bleeding commonly occurs in joints such as the elbows, knees, and ankles, as well as in muscles, often resulting in swelling, warmth, and severe pain. In patients with severe hemophilia A, bleeding into joints and muscles can occur even during normal daily activities. Repeated joint bleeding may lead to progressive joint damage, significantly affecting quality of life.

Since around 2000, prophylactic treatment with regular replacement of the missing factor VIII has become widely adopted. However, this approach requires intravenous infusions as frequently as once to several times per week. In addition, people with hemophilia A who developed an immune response to factor VIII, a non-self protein, resulting in the formation of factor VIII inhibitors, faced significant treatment challenges due to the limited treatment options available to them.

About the Lasker Foundation

Established in 1945 by Albert and Mary Lasker. Through its internationally renowned Lasker Awards, educational initiatives, and public advocacy, the Foundation raises awareness of the power of biomedical science to save and improve human lives. Through these efforts, the Foundation advocates for support for biomedical research, with the goal of advancing the prevention and treatment of disease and disability.

More information at laskerfoundation.org.

About the Lasker Awards

Renowned as America’s preeminent biomedical research prize, 360 laureates have received Lasker Medical Research Awards since 1945. Over these years, 101 Lasker Laureates have also received the Nobel Prize, including 28 in the last two decades. The laureates are selected by an international jury chaired by Joseph L. Goldstein, who received both the Lasker Award for Basic Medical Research and the Nobel Prize in Physiology or Medicine in 1985.

More details on the Lasker Award laureates, the full citations for each award category, video interviews and photos of the awardees, and additional information on the Foundation are available at laskerfoundation.org.

Collaboration with the Department of Pediatrics, Nara Medical University

The Department of Pediatrics at Nara Medical University has long been a pioneer in hemophilia care in Japan and has advanced both basic and clinical research in the field over many years.

Since 2003, Chugai has conducted collaborative research with the university. This collaboration has generated numerous achievements, including the establishment of coagulation assay systems for evaluating emicizumab.

In addition, the university made significant contributions to the clinical development of emicizumab, including its early clinical studies in Japan. Furthermore, during global clinical development, the network of international researchers and hemophilia specialists cultivated over many years by the Department of Pediatrics at Nara Medical University served as a major asset for Chugai as it entered a new therapeutic area.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at https://www.chugai-pharm.co.jp/english/.

Trademarks used or mentioned in this release are protected by law.

Excerpt from the electronic package insert information *Relevant sections only

4. Indications

For routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital hemophilia A (congenital factor VIII deficiency).

6. Dosage and Administration

Administer emicizumab (genetically engineered) by subcutaneous injection at a dose of 3 mg/kg once weekly for the first 4 weeks. One week after the fourth dose (Week 5 from the initial dose), administer one of the following maintenance regimens by subcutaneous injection:

1.5 mg/kg once every week

3 mg/kg once every two weeks

6 mg/kg once every four weeks

Sources:

Michael U. Callaghan, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

https://ashpublications.org/blood/article/137/16/2231/474603/Long-term-outcomes-with-emicizumab-prophylaxis-for (accessed September 2026)

Japanese Society on Thrombosis and Hemostasis (JSTH), Clinical Practice Guidelines

https://www.jsth.org/wordpress/guideline/index.html (in Japanese only, accessed September 2026)

Information Center for Specific Pediatric Chronic Diseases, 40. Hemophilia A

https://www.shouman.jp/disease/details/09_21_040/ (in Japanese only, accessed September 2026)

Additional Information:

Lasker Foundation

https://laskerfoundation.org/

Papers released alongside the Lasker Award announcement

JAMA: https://jamanetwork.com/

Proceedings of the National Academy of Sciences of the United Stated of America: https://www.pnas.org/

The New England Journal of Medicine: https://www.nejm.org/

Key publications and review articles on Emicizumab drug discovery

Takehisa Kitazawa, et al. Nature Medicine. 2012;18.(10);1570-1574. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

https://www.nature.com/articles/nm.2942

Zenjiro Sampei, et al. PLoS One. 2013;8(2);e57479. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057479

Atsushi Muto, et al. Journal of Thrombosis and Haemostasis. 2014;12(2):206-213. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

https://www.jthjournal.org/article/S1538-7836(22)03861-2/fulltext

Atsushi Muto, et al. Blood. 2014;124(20):3165-3171. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A

https://ashpublications.org/blood/article/124/20/3165/33262/Anti-factor-IXa-X-bispecific-antibody-ACE910

Takehisa Kitazawa, et al. Thrombosis and Haemostasis. 2017; 117(7);1348-1357. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

https://www.thieme-connect.de/products/ejournals/abstract/10.1160/TH17-01-0030

Takehisa Kitazawa, Midori Shima. Journal of Japanese Biochemical Society 89(3): 325-332. New challenge for treatment of hemophilia A by using bispecific antibody

https://seikagaku.jbsoc.or.jp/10.14952/SEIKAGAKU.2017.890325/index.html (In Japanese only)

Tomoyuki Igawa. Experimental Medicine, Vol. 36, No. 11, pp. 1823–1829.

The Impact of Next-Generation Antibody Therapeutics: Technology Development of Bispecific Antibodies and Drug Discovery, with a Focus on Next-Generation Antibody Therapeutics for Hemophilia

https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=201802264570677621 (In Japanese only)

Takehisa Kitazawa, Midori Shima. Int J Hemotol. 2020 Jan;111(1):20-30. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with factor VIIIa-cofactor activity.

https://link.springer.com/article/10.1007/s12185-018-2545-9

Takehisa Kitazawa, et al. Successful Drug Discovery vol 5. 2020. Discovery and Development of Emicizumab (HEMLIBRA® ): A Humanized Bispecific Antibody to Coagulation Factors IXa and X with a Factor VIII Cofactor Activity

https://onlinelibrary.wiley.com/doi/abs/10.1002/9783527826872.ch7

Takehisa Kitazawa, Kunihiro Hattori. Experimental Medicine, April 2021, Vol. 39, No. 6, pp. 971–975. Emicizumab Born from a Bold Idea: An Antibody that Replaces Blood Coagulation Factor Function

https://www.yodosha.co.jp/jikkenigaku/series.html?type=zokusouyaku (In Japanese only)

Biographies of the Laureates

https://www.chugai-pharm.co.jp/english/media/conference/files/20260909_eMaterial2.pdf

Message from the President and CEO

https://www.chugai-pharm.co.jp/english/media/conference/files/20260909_eMaterial3.pdf

About Hemophilia A

https://www.chugai-pharm.co.jp/english/media/conference/files/20260909_eMaterial4.pdf

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909923883/en/

Permalink

https://www.aetoswire.com/en/news/9092026572022

Contacts

For Media:

Chugai Pharmaceutical Co., Ltd.

Media Relations Group, Corporate Communications Dept.

E-mail: pr@chugai-pharm.co.jp

For Investors:

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group, Corporate Communications Dept.

E-mail: ir@chugai-pharm.co.jp

The Rock-It Company Expands Dynamic Dox to Provide ATA Carnet Services Across the US and Canada

 Expansion provides access and expert ATA Carnet services for customers across new regions

 

(BUSINESS WIRE)--The Rock-It Company announced today the expansion of Dynamic Dox, the industry-leading provider of ATA Carnets, to now service partners and projects based in the United States, Canada and beyond.

Following over a decade of expertise and leading service across the United Kingdom since 2014, Dynamic Dox will now provide new regions with dedicated document preparation for time-sensitive logistics projects, and urgent ATA Carnets for international shipments and critical business travel needs. The news of the expansion follows Dynamic Dox’s recent brand refresh, introducing an updated identity and connection to The Rock-It Company as Dynamic Dox By Rock-It. The expansion is led by Amanda Barlow, VP of Global ATA Carnets at The Rock-It Company, who has helped to drive the platform’s growth in ATA Carnets, customs services and beyond.

The Rock-It Company recently enabled the largest sporting event in history as the Official Logistics Provider of the FIFA World Cup 2026™ in Canada, USA and Mexico, and during the tournament relied on the fortified carnet services offered within this expansion. Dynamic Dox will continue to support global teams across mega events around the world in years to come.

The Rock-It Company and Dynamic Dox have garnered international recognition and support from leading organizations such as World ATA Carnet Council, US Council for International Business, and the UK National ATA Carnet Organisation. Over the past year and a half, The Rock-It Company and Dynamic Dox leadership have spoken at The World Chambers Congress, Association of Exporters and Importers (AAEI), AirCargo Conference, and London Chamber of Commerce and Industry (LCCI) events, to provide exporters with insights and strategies to optimize customs, ATA Carnets and global movements.

As part of The Rock-It Company, Dynamic Dox provides direct-to-customer offerings and service with 24-hour support, and also provides the global logistics platform with insight, strategy and access to unparalleled ATA Carnet solutions. The Rock-It Company represents a global platform of specialty logistics solutions including Rock-It Cargo, CARS By Rock-It, DIETL By Rock-It, and dedicated divisions across the Live Events and Luxury Goods landscape. Dynamic Dox now provides critical carnet services across the portfolio throughout the US and Canada.

About The Rock-It Company

The Rock-It Company is the global leader in mission-critical specialty logistics, trusted to move irreplaceable assets and power extraordinary moments across Live Events and Luxury Goods. Built on a 48-year legacy, Rock-It delivers multimodal freight forwarding, event logistics planning, specialized packing and storage, customs and ATA carnet services, insurance, on-site support, and more.

Rock-It manages the logistics behind concert touring, major sporting events, broadcast productions, film and media, corporate events, experiential activations, rapid response and infrastructure, and the transport and protection of fine art, rare automobiles, and other priceless collections. With access across 160+ countries and with more than 10,000 missions each year, Rock-It serves a diverse list of partners including the FIFA World Cup 2026, the Pebble Beach Concours D’Elegance®, RM Sotheby’s, leading hypercar OEMs, multiple Olympic committees, leagues and federations, and other leading brands across the globe.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909137375/en/

Permalink

https://aetoswire.com/en/news/909200265720023

Contacts

Angus Brown, SVP Marketing and Partnerships

angus.brown@rockitcompany.com

The Estée Lauder Companies Announces Expanded Roles for Brian Franz and Amber English

 Appointments Support the Company's Ongoing Transformation Through Beauty Reimagined and Continued Focus on Consumer-Centric Growth

(BUSINESS WIRE) -- The Estée Lauder Companies Inc. (NYSE: EL) today announced expanded leadership roles for two members of its Executive Team. Brian Franz has been appointed Chief Technology & Transformation Officer, expanding his responsibilities to include leading the company's enterprise-wide transformation. Amber English has been named President, Digital & Online, The Americas and Global Amazon Lead, assuming new enterprise-wide responsibility for The Estée Lauder Companies’ global relationship with Amazon. Both will continue to report directly to Stéphane de La Faverie, President and Chief Executive Officer, and remain members of The Estée Lauder Companies’ Executive Team. Both appointments are effective immediately.

“Transformation at The Estée Lauder Companies is not a moment in time or a project with an end date. It’s a part of our strategy and is how we operate,” said de La Faverie. “Consumer expectations continue to rapidly evolve, and we must keep changing with them. Brian and Amber have each played important roles in advancing our consumer-centric transformation, using technology, digital commerce, and strategic partnerships to help our brands reach consumers in more relevant and differentiated ways. Their expanded responsibilities recognize the deep digital transformation underpinning the company’s next phase of growth and will help us move faster, strengthen our One ELC operating model, and continue building the capabilities needed for the future.”

Brian Franz: Technology as a Driving Force of Ongoing Transformation

In his expanded role, Franz will lead The Estée Lauder Companies’ ongoing, enterprise-wide transformation, bringing together initiatives focused on driving revenue and improving productivity, including the continued operationalization of the company’s Enterprise Business Services program. He will advance the company’s transformation agenda by accelerating AI-enabled processes, building critical technology skills across the organization, and driving next-generation ways of working. In addition to his new responsibilities, Franz will continue to oversee the Technology, Data & Analytics function globally, harnessing these capabilities to drive growth, efficiency, and ongoing transformation across the company.

Since joining the company in April 2025, Franz has advanced its strategic technology ecosystem, including a global partnership with Shopify to unify The Estée Lauder Companies’ omnichannel commerce foundation and support seamless consumer shopping experiences. He has also been instrumental in launching the company’s partnership with Accenture, which is simplifying shared services through greater standardization and scale. Together, these efforts demonstrate how technology can accelerate transformation across the enterprise.

“Over the past 18 months, we have focused on building the technology-driven foundations that will enable the company’s future and, with that, have embedded an expectation among our team for constant evolution and improvement,” said Franz. “How we work, make decisions, and ultimately serve our consumers will never be stagnant. Technology is one of the most powerful tools we have to make that evolution real, and I am excited to take on this expanded responsibility as we continue building a faster, simpler, and more connected company.”

Amber English: Advancing the Americas Digital Presence and Global Amazon Relationship

In her expanded role, English will lead and unify The Estée Lauder Companies’ global Amazon business, currently spanning 13 brands across 11 markets, to accelerate digital growth and create greater connectivity across markets. While continuing as President, Digital & Online, The Americas, she will oversee global consumer experience, creator commerce, cross-market sharing of best practices, and the company’s global partnership with Amazon.

English joined the company in December 2021 as Senior Vice President and General Manager, eCommerce, North America. She led the company’s entrance into Amazon Premium Beauty and TikTok Shop U.S. Since then, she has built the capabilities, expertise, and operating model to accelerate digital commerce across brand.coms, retailer.coms and social commerce in The Americas, building a scalable model that has become a blueprint for markets around the world. Her leadership in The Americas has helped drive the company’s broader global acceleration of digital commerce. In fiscal 2026, Online1 accounted for 34% of the company’s reported net sales, a three percentage point increase from fiscal 2025.

“Our work in The Americas has demonstrated what is possible when we combine strong brand building, differentiated consumer experiences, and the scale of digital commerce,” said English. “Amazon has been an exceptional partner, and this expanded global remit gives us the opportunity to scale what we’ve learned across markets while continuing to create differentiated experiences for consumers around the world.”

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary, NIOD, Avestan and Loopha, and Balmain Beauty.

ELC-C

_________________________

1 Online sales include sales we make directly to our consumers through our brand.com sites and through third party platforms. It also includes estimated sales of our products through our retailers’ websites.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260908417554/en/

Permalink

https://aetoswire.com/en/news/0909202657176

Contacts

Media Relations:

Brendan Riley

briley@estee.com

Investor Relations:

Rainey Mancini

rmancini@estee.com